Table 4 Toxicity in subsequent lines of treatment (Grade ≥ 2)
From: A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it?
| Â | PLD arm | Other treatment |
|---|---|---|
Neutropenia |  14% |   20% |
Thrombocytopenia |  7% |   12% |
Anemia |  1% |   3% |
Hand–foot syndrome |  5% |   0% |
Oral toxicity |  5% |   3% |
Neurological toxicity |  1% |   7% |